<html>

<head>
   <meta http-equiv="Content-Language" content="en-us">
   <meta name="GENERATOR" content="Microsoft FrontPage 5.0">
   <meta name="ProgId" content="FrontPage.Editor.Document">
   <meta http-equiv="Content-Type" content="text/html; charset=windows-1252">
   <title>Parkinson's Disease </title>
   <style>
      p.MsoNormal {
         mso-style-parent: "";
         margin-bottom: .0001pt;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.MsoBodyText {
         margin-bottom: .0001pt;
         line-height: 150%;
         font-size: 14.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.MsoBodyText2 {
         margin-bottom: .0001pt;
         text-align: justify;
         line-height: 150%;
         layout-grid-mode: char;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.Index {
         margin-bottom: .0001pt;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }
   </style>
</head>

<body>

   <p class="MsoNormal" align="center"><b><u>
            <span style="font-family: Arial">
               <font size="4">Parkinson's Disease </font>
            </span></u></b></p>
   <p class="MsoNormal" align="center" style="text-align: center"><b><u>
            <span style="font-family: Arial">
               <font size="4">Topic Highlights</font>
            </span></u></b></p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Parkinson's disease is a chronic and progressive neurodegenerative disorder.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial">
         <font size="4">It affects the neurons situated in the area of brain that controls movements.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial">
         <font size="4">The symptoms result from a decrease in dopamine levels.</font>
      </span>
   </p><br>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial">
         <font size="4">This animation provides an illustrated insight into what causes Parkinson's disease, classical
            symptoms of Parkinson's disease, the pathophysiology of the disease, disease diagnosis, and treatment.
         </font>
      </span>
   </p><br>
   <p class="MsoNormal" align="center" style="line-height: 150%">
      <b><u><span style="line-height: 150%; font-family: Arial">
               <font size="4">
                  Transcript</font>
            </span></u></b>
   </p>
   <p class="MsoNormal" style="line-height: 150%" align="left"><b>
         <span style="line-height: 150%; font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">
            <a href="https://en.m.wikipedia.org/wiki/Parkinson%E2%80%99s_disease"
               style="color: blue; text-decoration: underline; text-underline: single">Parkinson's disease</a> is a
            chronic progressive and degenerative disease affecting the neurons in the area of the brain which control
            muscle movement. The disease worsens gradually over time leading to disability.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Symptoms of Parkinson's disease in the initial phase are subtle and progress gradually. The
            initial phase may last for a very long time before the disease deteriorates further. As the disease
            progresses, the classic symptoms of Parkinson's appear- <a href="https://en.m.wikipedia.org/wiki/Tremors"
               style="color: blue; text-decoration: underline; text-underline: single">tremors</a>, <a
               href="https://en.m.wikipedia.org/wiki/Rigidity_%28neurology%29"
               style="color: blue; text-decoration: underline; text-underline: single">rigidity </a>
            and slowing of movements or <a href="https://www.wemove.org/bradykinesia/"
               style="color: blue; text-decoration: underline; text-underline: single">bradykinesia</a>.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/Dopaminergic_neuron#Functions_in_the_brain"
               style="color: blue; text-decoration: underline; text-underline: single">Dopaminergic neurons</a> of the
            <a href="https://en.m.wikipedia.org/wiki/Substantia_Nigra"
               style="color: blue; text-decoration: underline; text-underline: single">substantia nigra</a> are
            destroyed in Parkinson's disease, which results in a decrease in the secretion of the neurotransmitter
            dopamine. This presentation focuses on causes, symptoms, diagnosis and treatment of Parkinson's disease.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">
            Parkinson's disease is a <a href="https://en.m.wikipedia.org/wiki/Neurodegenerative_disease"
               style="color: blue; text-decoration: underline; text-underline: single">neurodegenerative disease</a>
            causing motor function disorders that occur as a result of disturbances in the region of the brain that
            plays a crucial role in regulating smooth motor functions. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Neurological syndromes are exhibited in some combination of the following: resting tremors,
            rigidity, bradykinesia and loss of postural reflexes. Parkinson's disease is more common in older people,
            the cause of which is not known.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Although practically the entire brain contributes to body movements, any voluntary movement of
            the body involves the motor cortex and numerous other neural systems and their sensory-motor coordination.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/Primary_motor_cortex"
               style="color: blue; text-decoration: underline; text-underline: single">The primary motor cortex</a> is
            located in the <a href="https://en.m.wikipedia.org/wiki/Frontal_lobe"
               style="color: blue; text-decoration: underline; text-underline: single">frontal lobe</a> together with
            the <a href="https://en.m.wikipedia.org/wiki/Secondary_motor_cortex"
               style="color: blue; text-decoration: underline; text-underline: single">secondary motor cortices</a>. The
            secondary motor cortices consist of the posterior parietal cortex, the <a
               href="https://en.m.wikipedia.org/wiki/Premotor_cortex"
               style="color: blue; text-decoration: underline; text-underline: single">premotor cortex</a> and the <a
               href="https://en.m.wikipedia.org/wiki/Supplementary_motor_area"
               style="color: blue; text-decoration: underline; text-underline: single">supplementary motor area</a>
            (SMA) involved in the planning, coordination and execution of voluntary movement.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The <a href="https://en.m.wikipedia.org/wiki/Basal_ganglia"
               style="color: blue; text-decoration: underline; text-underline: single">basal ganglia</a> at the base of
            the <a href="https://en.m.wikipedia.org/wiki/Cerebrum"
               style="color: blue; text-decoration: underline; text-underline: single">cerebrum </a> and in the upper
            brainstem, buried deep inside the cortex, include the <a href="https://en.m.wikipedia.org/wiki/Striatum"
               style="color: blue; text-decoration: underline; text-underline: single">striatum</a> and the <a
               href="https://en.m.wikipedia.org/wiki/Substantia_nigra"
               style="color: blue; text-decoration: underline; text-underline: single">substantia nigra</a>. The <a
               href="https://en.m.wikipedia.org/wiki/Caudate_Nucleus"
               style="color: blue; text-decoration: underline; text-underline: single">caudate nucleus</a>, <a
               href="https://en.m.wikipedia.org/wiki/Putamen"
               style="color: blue; text-decoration: underline; text-underline: single">putamen</a>, <a
               href="https://en.m.wikipedia.org/wiki/Globus_pallidus"
               style="color: blue; text-decoration: underline; text-underline: single">globus pallidus</a> and <a
               href="https://en.m.wikipedia.org/wiki/Subthalamic_nucleus"
               style="color: blue; text-decoration: underline; text-underline: single">subthalamic nucleus</a> (STN)
            receive information from several different regions of the cerebral cortex. The caudate nucleus and putamen
            form part of the neuronal structure called striatum. The basal ganglia plays an important role in
            coordinating voluntary movement using the direct and indirect pathways. The caudate receives the information
            from the associated cortices that control motor areas in the frontal lobe, while the diverse sensory
            information is received by the putamen. Together with the substantia nigra the basal ganglia controls
            voluntary movement. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The substantia nigra is located in the <a href="https://en.m.wikipedia.org/wiki/Mesencephalon"
               style="color: blue; text-decoration: underline; text-underline: single">mesencephalon</a> or the
            midbrain. The axons leaving this area innervate the major input structures of the basal ganglia. It is also
            the site for synthesis of the neurotransmitter <a href="https://en.m.wikipedia.org/wiki/Dopaminergic_neuron"
               style="color: blue; text-decoration: underline; text-underline: single">dopamine</a>. The strong input
            signals for movement emanate from the dopaminergic neurons in the substantia nigra. The two types of
            dopamine receptors-- the excitatory <a href="https://en.m.wikipedia.org/wiki/D1_receptor"
               style="color: blue; text-decoration: underline; text-underline: single">D1</a> and the inhibitory <a
               href="https://en.m.wikipedia.org/wiki/D2_receptors"
               style="color: blue; text-decoration: underline; text-underline: single">D2 receptors</a> provide the
            balance of starting and stopping a movement.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The basal ganglia and cerebellum work in close coordination with each other and also with the
            motor cortex. The cerebellum usually sends out excitatory signals whereas the basal ganglia send out
            inhibitory signals. The cerebellum plays a role in motor coordination in both the acceleration and the
            braking phases of body movements.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Movement is facilitated by the direct pathway. When input from the cortex reaches the striatum,
            and the dopamine from the substantia nigra reach the D1 receptors, the <a
               href="https://en.m.wikipedia.org/wiki/GABAergic"
               style="color: blue; text-decoration: underline; text-underline: single">GABAergic</a> neurons inhibit the
            <a href="https://en.m.wikipedia.org/wiki/Internal_globus_pallidus"
               style="color: blue; text-decoration: underline; text-underline: single">GPi</a> which in turn sends
            inhibitory signals to the thalamus.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">With GPi inhibited, the motor <a href="https://en.m.wikipedia.org/wiki/Thalamus"
               style="color: blue; text-decoration: underline; text-underline: single">thalamus</a>, relieved from
            inhibition, provides the frontal cortex with the appropriate motor programs for the desired movement. The
            motor cortex then triggers upper motor neurons to signal the lower motor neurons to perform the movement.
            The sensory feedback then enables actual execution of the movement.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The indirect pathway inhibits unwanted movements. Nullifying the disinhibitory actions of the
            direct pathway and restoring the inhibition of the motor thalamus stop the movement. The <a
               href="https://en.m.wikipedia.org/wiki/Subthalamic_nucleus"
               style="color: blue; text-decoration: underline; text-underline: single">subthalamic nucleus</a> (STN)
            that is responsible for this is under inhibition by the external segment of the <a
               href="https://en.m.wikipedia.org/wiki/Globus_pallidus"
               style="color: blue; text-decoration: underline; text-underline: single">Globus pallidus</a> or GPe. This
            happens when the inhibition is lifted and the STN excites the inhibitory GPi that brings the motor thalamus
            to its original state. The STN also excites the substantia nigra, which also inhibits the motor thalamus.
            These actions of STN in influencing both substantia nigra and the GPi serve to halt the movement.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Normally excitatory and inhibitory signals balance each other in such a way that the body is
            able to carry out smooth and coordinated movements. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">In Parkinson's disease the dopaminergic neurons projecting from the substantia nigra to the
            putamen portion of striatum are destroyed. The symptoms appear when the cells become impaired and die. The
            symptoms are due to the decrease in dopamine levels, which occur due to the decreased number of substantia
            nigra neurons.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">This results in the abnormal activity in the putamen, causing the primary features of the
            disease. When substantia nigra projections to the putamen are impaired, the globus pallidus interna and
            subthalamic nucleus begin to function abnormally resulting in the insufficient control of motor functions by
            the brain.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Parkinson's disease is caused by a loss of striato-nigral dopaminergic cells but it is not known
            why this occurs. It is believed that environment and genetics play a role. Certain medications, toxins and
            other diseases can produce symptoms similar to Parkinson's disease and this is known as secondary
            Parkinsonism, which may be reversible.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Symptoms of Parkinson's disease may be subtle in the initial phase of the disease. They may
            include tremors, mumbling speech, difficulty in getting up from a chair or turning in bed, cramped
            handwriting or slowed walking. The typical clinical features of Parkinson's disease are a rest tremor,
            rigidity, and bradykinesia, or slowness in the execution of movement. The resting tremor often increases
            with walking and decreases with posture holding or action. The tremor is asymmetrical and affects the hands
            and legs. Victims also show signs of smaller writing. Non-motor symptoms such as memory difficulties,
            bladder disturbance, and depression are also seen.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The diagnosis relies entirely on clinical judgment and depends upon a careful history and
            examination of the patient. Neurological examinations are carried out and the changes in gait, handwriting,
            facial expressions, difficulty in getting up from a chair, walking, etc. are observed.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">There is no known drug treatment to retard the progression of the pathophysiology of Parkinson's
            disease. The current aim of treatment is to manage the symptoms to help the patient continue his/her
            day-to-day activities. The doctor may choose a single medication or combine two or three depending on the
            individual case.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/L-DOPA"
               style="color: blue; text-decoration: underline; text-underline: single">Levodopa</a> is the most powerful
            medication used for treating Parkinson's disease. Dopamine cannot be given to patients of Parkinson's
            disease, as it is unable to cross the blood-brain barrier. Levodopa is a precursor of dopamine and is itself
            inactive. It is converted to dopamine by the action of an enzyme, called <a
               href="https://en.m.wikipedia.org/wiki/Dopa_decarboxylase"
               style="color: blue; text-decoration: underline; text-underline: single">dopa decarboxylase</a>. Levodopa
            can cross the blood-brain barrier and is converted to dopamine within the brain and the rest of the body.
            Peripheral metabolism of Levodopa is undesirable as this leads to a number of adverse effects including
            vomiting and low blood pressure.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/Decarboxylase_inhibitor"
               style="color: blue; text-decoration: underline; text-underline: single">Decarboxylase inhibitors</a> that
            prevent metabolism of Levodopa to dopamine outside the brain enhance the efficacy of Levodopa. These drugs
            by themselves have no effect on the symptoms of Parkinson's disease. But when given along with Levodopa they
            block the enzyme dopa decarboxylase in all the sites except the brain, as they are unable to penetrate the
            blood brain barrier. This means that only Levodopa which enters the brain is metabolized to dopamine. Two
            such dopa decarboxylae inhibitors are <a href="https://en.m.wikipedia.org/wiki/Carbidopa"
               style="color: blue; text-decoration: underline; text-underline: single">Carbidopa</a> and <a
               href="https://en.m.wikipedia.org/wiki/Benserazide"
               style="color: blue; text-decoration: underline; text-underline: single">Benserazide</a>.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Another group of drugs commonly used to treat Parkinson's disease are <a
               href="https://en.m.wikipedia.org/wiki/Dopamine_agonists"
               style="color: blue; text-decoration: underline; text-underline: single">Dopamine agonists</a>, which
            stimulate the brain dopamine receptors. Examples are <a href="https://en.m.wikipedia.org/wiki/Bromocriptine"
               style="color: blue; text-decoration: underline; text-underline: single">bromocriptine</a>, <a
               href="https://en.m.wikipedia.org/wiki/Ropinirole"
               style="color: blue; text-decoration: underline; text-underline: single">ropinirole</a>, <a
               href="https://en.m.wikipedia.org/wiki/Pergolide"
               style="color: blue; text-decoration: underline; text-underline: single">pergolide</a> and <a
               href="https://en.m.wikipedia.org/wiki/Pramipexole"
               style="color: blue; text-decoration: underline; text-underline: single">pramipexole</a>.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">
            Levodopa and dopamine are metabolized by two enzymes, <a
               href="https://en.m.wikipedia.org/wiki/Monoamine_oxidase"
               style="color: blue; text-decoration: underline; text-underline: single">mono-amine oxidase type B</a>
            (MAO-B), and <a href="https://en.m.wikipedia.org/wiki/COMT"
               style="color: blue; text-decoration: underline; text-underline: single">catechol-O-methyl-transferase</a>
            (COMT). Action of these enzymes outside the blood-brain barrier decreases levels of Levodopa entering the
            brain. Therefore these enzymes are inhibited so that there is a more stable and constant supply of Levodopa,
            which makes its beneficial effects last longer.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">MAO-B inhibitors and COMT inhibitors, which inhibit these enzymes, are used to treat Parkinson's
            disease. These inhibitors allow a larger amount of Levodopa to reach the brain, which raises dopamine
            levels.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/Selegiline"
               style="color: blue; text-decoration: underline; text-underline: single">Selegiline</a> is an MAO-B
            inhibitor, which may be used alone or in conjunction with other dopaminergic drugs. <a
               href="https://en.m.wikipedia.org/wiki/Tolcapone"
               style="color: blue; text-decoration: underline; text-underline: single">Tolcapone</a> and <a
               href="https://en.m.wikipedia.org/wiki/Entacapone"
               style="color: blue; text-decoration: underline; text-underline: single">Entacapone</a> are COMT
            inhibitors, which by themselves cannot help alleviate the symptoms of Parkinson's disease but must be
            combined with Levodopa and <a href="https://en.m.wikipedia.org/wiki/Carbidopa"
               style="color: blue; text-decoration: underline; text-underline: single">carbidopa</a>. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/Amantidine"
               style="color: blue; text-decoration: underline; text-underline: single">Amantidine</a> was originally
            developed as an antiviral drug. It has a mild anti-Parkinsonian effect and may be useful to treat Levodopa
            induced dyskinesias (abnormal involuntary movements and postures.)</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/Anticholinergics"
               style="color: blue; text-decoration: underline; text-underline: single">Anticholinergics</a> may help in
            controlling tremor. Examples are <a href="https://en.m.wikipedia.org/wiki/Trihexyphenidyl"
               style="color: blue; text-decoration: underline; text-underline: single">Trihexyphenidyl</a>, <a
               href="https://en.m.wikipedia.org/wiki/Benztropine"
               style="color: blue; text-decoration: underline; text-underline: single">Benztropine</a>
            and <a href="https://en.m.wikipedia.org/wiki/Orphenadrine"
               style="color: blue; text-decoration: underline; text-underline: single">Orphenadrine</a>. They may also
            help in controlling salivation and drooling.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Surgery was the primary for treatment of Parkinson's disease until the advent of Levodopa. Now
            surgical procedures are recommended for patients who have developed severe motor complications. Surgery may
            involve transplantation of fetal dopaminergic cells, selective destruction of certain parts of the brain
            (eg. <a href="https://en.m.wikipedia.org/wiki/Pallidotomy"
               style="color: blue; text-decoration: underline; text-underline: single">Pallidotomy</a>) or <a
               href="https://en.m.wikipedia.org/wiki/Deep_brain_stimulation"
               style="color: blue; text-decoration: underline; text-underline: single">deep brain stimulation</a>. The
            role of surgery remains uncertain and is probably only appropriate for a small number of patients.</font>
      </span>
   </p><br><br>

   <center>
      <div id="google_translate_element"></div>
   </center>
   

   

<script src="https://kit.fontawesome.com/a7d3f41661.js" crossorigin="anonymous"></script>
</body>

</html>